EQ - CIK 0001746466
Equillium, Inc. trades as EQ. In its fiscal 2024 annual report the company posted revenue of $41.09M, up 13.9% from the prior year and net income of -$22.40M. This page tracks Equillium, Inc. through 446 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -396.1% to -19.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-27 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| SCHEDULE 13G | - | 2026-05-07 |
| EFFECT | - | 2026-04-16 |
| Annual report to shareholders | ARS | 2026-04-15 |
The largest companies sharing Equillium, Inc.'s SEC industry classification (pharmaceutical preparations).
Equillium, Inc. reported revenue of $41.09M for fiscal year 2024, an increase of 13.9% year over year.
In its latest fiscal year Equillium, Inc. reported a net loss of $22.40M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.